Disclosures: Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant, Andrea Mospan: Nothing to Disclose, Breda Munoz: Nothing to Disclose, Rohit Loomba: Eli Lilly and Company: Consultant, Michael Fried: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Philip Newsome: Novo Nordisk: Consultant, B Ingelheim: Consultant, Madrigal: Consultant, 89 Bio: Consultant, Sagimet: Consultant, Echosens: Speaking and Teaching, Eli Lilly: Speaking and Teaching, Zydus Therapeutics: Consultant, Abbott: Speaking and Teaching, Kenneth Cusi: Nothing to Disclose, Arun Sanyal: Genfit, Akarna, Tiziana, Durect, Inversago, Hemoshear, North: Stock - publicly traded company, Astra Zeneca ( 60K), Boston Pharmaceutical ( 50% OoF tiles were flagged as inadequate quality for reporting
It also supports cognitive functions and aids in the management of homocysteine levels, contributing to cardiovascular health
(3) To examine relationships between metabolites and microbial taxa (fecal and ruminal fluid)
Currently sold under the brand names Alphagan and Brymont (Allergan, Inc., Irvine, CA, USA), brimonidine was patented in 1972 and became commercially available as a glaucoma treatment as an eyedrop formulation containing brimonidine tartrate
